Target Pathogens

The ID Consortium evaluates pathogens based on occurrence, threat severity, and treatment availability. Our lab and therapeutic access services currently focus on the following pathogens:


  • Multidrug-resistant Clostridium difficile
  • Carbapenem-resistant Enterobacteriaceae
  • Multidrug-resistant Acinetobacter
  • Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs)
  • Vancomycin-resistant Enterococcus (VRE)
  • Multidrug-resistant Pseudomonas aeruginosa
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Drug-resistant Streptococcus pneumoniae
  • Vancomycin-resistant Staphylococcus aureus (VRSA)
  • Mycobacterium tuberculosis

Viruses (life-threatening cases)

  • Respiratory Syncytial Virus (RSV)
  • Influenza
  • Parainfluenza
  • Cytomegalovirus (CMV)
  • Adenovirus


  • Fluconazole-resistant Candida
  • Multidrug-resistant Candida spp.
  • Triazole-resistant Aspergillus spp
  • Fusarium spp
  • Scedosporium spp
If you have a patient with a life threatening multi-drug resistant infection, and you do not see the pathogen listed, please contact us to discuss.
Copyright @ 2015 ID Consortium